What is the optimal regimen for vitamin D?

Kidney International, Supplement

Volumn 56, Issue 73, 1999, Pages

  Cunningham, John ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM; DOXERCALCIFEROL; MINERAL; PARICALCITOL; PHOSPHATE; VITAMIN D DERIVATIVE; DRUG DERIVATIVE; ERGOCALCIFEROL; PARATHYROID HORMONE; VITAMIN D;

ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHRONOTHERAPY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SELECTIVITY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MINERAL METABOLISM; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION; ANIMAL; BONE; DRUG EFFECT; METABOLISM; REVIEW; SECRETION;

ANIMALS; BONE AND BONES; CALCITRIOL; ERGOCALCIFEROLS; HUMANS; PARATHYROID HORMONE; VITAMIN D;

EID: 0033401470     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.07307.x     Document Type: Article

References (30)

1. SLATOPOLSKY E, DELMEZ JA: Pathogenesis of secondary hyperparathyroidism. Am J Kid Dis 23:229-236, 1994
2. SLATOPOLSKY E, MARTIN K, HRUSKA K: Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol 239:F1-F12, 1980
3. CUNNINGHAM J: Parathyroid pathophysiology in uremia. Nephrol Dial Transplant 11:S106-S110, 1996
4. PARFITT AM: The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52:3-9, 1997
5. NAVEH-MANY T, RAHAMIMOV R, LIVNI N, SILVER J: Parathyroid proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, vitamin D. J Clin Invest 96:1786-1793, 1995
6. 3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 53:93-101, 1989
7. SHERRARD DJ, HERCZ G, PEI Y, MALONEY NA, GREENWOOD C, MANUEL A, SAIPHOO C, FENTON SS, SEGRE GV: The spectrum of bone disease in end-stage renal failure: An evolving disorder. Kidney Int 43:436-442, 1993
8. COURNOT-WITMER G, ZlNGRAFF J, PLACHOT JJ, ESCAIG F, LEFÈVRE R, BOUMATI P, BOURDEAU A, GARABÉDIAN M, GALLE P, BOURDON R, DRÜEKE T, BALSAN S: Aluminum localizaton in bone from hemodialyzed patients: relationship to matrix mineralization. Kidney Int 20:375-385, 1981
9. DELMEZ JA, SLATOPOLSKY E: Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19:303-317, 1992
10. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients - a national study. Am J Kidney Dis 31:601-617, 1998
11. DENDA M, FINCH J, SLATOPOLSKY E: Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28:596-602, 1996
12. BRICKMAN S, COBURN JW, NORMAN AW: Action of 1,25-dihydroxycholecalciferol, a potent, kidney produced metabolite of vitamin D in uremic man. N Engl J Med 287:891-895, 1972
13. CHALMERS TM, HUNTER JO, DAVIE MW, SZAZ KF, PELC B, KODICEK E: 1-alfa-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure. Lancet 2:696-699, 1973
14. 3 on circulating parathyroid hormone in acute renal failure. J Clin Endocrinol Metab 53:823-827, 1981
15. SLATOPOLSKY E, WEERTS C, THIELAN J, HORST R, HARTER H, MARTIN KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
16. 3 in patients on chronic hemodialysis. Am J Nephrol 12:311-318, 1992
17. MOE SM, KRAUS MA, GASSENSMITH CM, FINEBERG NS, GANNON FH, PEACOCK M: Safety and efficacy of pulse and daily calcitriol in patients on CAPD. a randomised trial. Nephrol Dial Transplant 13:1234-1241, 1998
18. KWAN JTC, ALMOND MK, BEER JC, NOONAN K, EVANS SJW, CUNNINGHAM J: 'Pulse' oral calcitriol in uracmic patients: rapid modification of parathyroid response to calcium. Nephrol Dial Transplant 7:829-834, 1992
19. MARTIN KJ, BALLAL HS, DOMOTO DT, BLAYLOCK S, WEINDEL M: Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. Am J Kidney Dis 19:540-545, 1992
20. FISCHER ER, HARRIS DCH: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 40:216-220, 1993
21. COBURN JW, FRAZAO J: Calcitriol in the management of renal osteodystrophy. Semin Dial 9:316-326, 1996
22. 3 in man. J Clin Invest 57:1540-1547, 1976
23. BROWN A: Vitamin D analogs. Am J Kidney Dis 32:S25-S39, 1998
24. BROWN AJ, RITTER CR, FINCH JL, MORRISSEY J, MARTIN KJ, MURAYAMA E, NISHII Y, SLATOPOLSKY E: The non calcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728-732, 1989
25. KUROKAWA K, AKIZAWA T, SUZUKI M, AKIBA T, OGATA E, SLATOPOLSKY E: Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients. Results of a preliminary study. Nephrol Dial Transplant 11:S121-S124, 1996
26. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860, 1995
27. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30:105-112, 1997
28. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427-1432, 1998
29. 3 in rats and monkeys. Endocrinology 136:4749-4753, 1995
30. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51:317-323, 1997